MA41432A - Composition pharmaceutique pour le traitement de maladies gastro-intestinales - Google Patents

Composition pharmaceutique pour le traitement de maladies gastro-intestinales

Info

Publication number
MA41432A
MA41432A MA041432A MA41432A MA41432A MA 41432 A MA41432 A MA 41432A MA 041432 A MA041432 A MA 041432A MA 41432 A MA41432 A MA 41432A MA 41432 A MA41432 A MA 41432A
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
gastrointestinal
diseases
Prior art date
Application number
MA041432A
Other languages
English (en)
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA41432A publication Critical patent/MA41432A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA041432A 2015-01-30 2016-01-27 Composition pharmaceutique pour le traitement de maladies gastro-intestinales MA41432A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물

Publications (1)

Publication Number Publication Date
MA41432A true MA41432A (fr) 2017-12-05

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041432A MA41432A (fr) 2015-01-30 2016-01-27 Composition pharmaceutique pour le traitement de maladies gastro-intestinales

Country Status (19)

Country Link
EP (1) EP3250199A4 (fr)
JP (1) JP6419347B2 (fr)
KR (2) KR101583452B1 (fr)
CN (1) CN107205947B (fr)
AR (1) AR105413A1 (fr)
CL (1) CL2017001680A1 (fr)
CO (1) CO2017006222A2 (fr)
EA (1) EA032385B9 (fr)
EC (1) ECSP17038599A (fr)
GE (2) GEP20196941B (fr)
MA (1) MA41432A (fr)
MX (1) MX375765B (fr)
MY (1) MY195824A (fr)
PE (1) PE20171340A1 (fr)
PH (1) PH12017550051A1 (fr)
SA (1) SA517382016B1 (fr)
TW (1) TWI635859B (fr)
UA (1) UA116517C2 (fr)
WO (1) WO2016122226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (fr) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Composition pharmaceutique comprenant du lénalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (fr) * 1989-06-14 1991-01-30 Warner-Lambert Company Un modèle de structure de système craniomandibulaire humain
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
ATE213635T1 (de) * 1994-04-26 2002-03-15 Chugai Pharmaceutical Co Ltd Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
JP2001513570A (ja) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー 上部胃腸管不調治療用複合製剤
WO2000078307A1 (fr) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
KR101617054B1 (ko) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 고형내복제제
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
JP6419347B2 (ja) 2018-11-07
WO2016122226A2 (fr) 2016-08-04
EP3250199A4 (fr) 2018-08-08
MX2017007567A (es) 2017-10-19
KR20160094268A (ko) 2016-08-09
KR101583452B1 (ko) 2016-01-11
PE20171340A1 (es) 2017-09-13
ECSP17038599A (es) 2017-09-29
PH12017550051A1 (en) 2018-01-29
CN107205947B (zh) 2020-05-22
GEAP201814551A (en) 2018-08-27
KR101583452B9 (ko) 2022-05-02
TW201639559A (zh) 2016-11-16
EA201791458A1 (ru) 2017-11-30
GEP20186941B (en) 2019-01-10
WO2016122226A3 (fr) 2016-09-15
SA517382016B1 (ar) 2021-03-18
EA032385B1 (ru) 2019-05-31
CL2017001680A1 (es) 2018-01-12
CN107205947A (zh) 2017-09-26
JP2018503672A (ja) 2018-02-08
BR112017013857A2 (pt) 2018-02-27
AR105413A1 (es) 2017-10-04
CO2017006222A2 (es) 2017-09-20
TWI635859B (zh) 2018-09-21
MX375765B (es) 2025-03-07
UA116517C2 (uk) 2018-03-26
EA032385B9 (ru) 2019-07-31
EP3250199A2 (fr) 2017-12-06
GEP20196941B (en) 2019-01-10
MY195824A (en) 2023-02-22

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3378484A4 (fr) Composition pharmaceutique pour le traitement de la fibrose cardiaque
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3288565A4 (fr) Composition de matrice extracellulaire pour le traitement du cancer ou des maladies immunologiques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques
EP3329929A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la sécheresse oculaire
EP3373931A4 (fr) Composés hétérocycliques pour le traitement de maladies